Fujitsu launched a new cloud-based platform that allows users to securely collect and leverage health-related data.
The new platform automatically converts medical data from medical institutions' electronic medical records to conform with the next-generation standards framework HL7 FHIR,
Consenting patients can securely store personal health information such as vital data, step counts, and calorie consumption.
These are converted into non-personally identifiable information on the platform, which supports medical institutions and pharmaceutical companies in performing data analysis and R&D activities.
The new offering represents Fujitsu’s ongoing efforts to promote digital transformation in the medical field and contribute to the creation of a healthy society.
Fujitsu will also use the platform to develop a data portability service that enables patients to view their medical data on their smartphones and allows medical institutions to conduct a highly accurate analysis of shared medical data on the platform.
Fujitsu said it aims to leverage this platform to realize an AI and IoT-based preventive healthcare system and cooperate with various medical institutions and companies to realize a digital health ecosystem.


US Appeals Court Upholds Anthropic AI Supply Chain Ban
Soybean Futures Slip as Traders Await Trump-Xi Trade Signals
Meta Connect Spotlights Camera-Free Smart Glasses Amid Privacy Concerns
U.S. Dollar Hits Two-Month High as Oil, Treasury Yields Surge
FDA Investigates New Cyclospora Outbreak as U.S. Cases Continue to Rise
OpenAI Agent Breaches Australia Medicare Data Portal
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal
Japan Private-Sector Growth Slows as Domestic Demand Weakens
DaVoice Sues Perplexity AI Over Trade Secrets
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline
Airbus Finds A321neo Fuselage Quality Issue
Alcohol is one of the most dangerous drugs, yet its presence is ubiquitous in social settings and celebrations
Novartis Shares Plunge After Muscle Drug Fails Phase III Trial
Meta Unveils Muse Charm AI Device, Expands Smart Glasses Lineup
Novo Nordisk Strikes €1.17 Billion Nanexa Drug Delivery Deal 



